Medical Doctor Program year 2025 Reported 2019–2025 Source: CMS Open Payments, 2026 publication

Jaffar Khan

Cardiovascular Disease Washington, DC Medical Doctor

NPI 1346805322 CMS profile 6139659

110 Irving St Nw Rm 4B1, Washington, DC 20010

Open in the dashboard

General payments

$317,757

401 records reported · program years 2019–2025

Research payments

$8,313

Paid to them · 12 records reported · program years 2019–2025

Ownership & investment interest

$0

None reported

Research they led as principal investigator

$12,673 paid to institutions, not to them · program year 2025

Through program year 2025, Jaffar Khan of Washington, DC is reported in the CMS Open Payments database as having received $317,757 across 401 general payments and $8,313 in research payments paid to them. Separately, studies naming them as principal investigator received $12,673 in research payments, paid to institutions rather than to them.

No combined total General, research and ownership are kept apart. Each is reported under its own rules, and ownership is not money that moved at all but the value of a stake held. A meal, a clinical trial grant and a shareholding do not add up to anything meaningful, so this site does not add them. The principal-investigator line is research money paid to institutions for studies they led — not to them — and is not added to anything either.

General payments for this record sit in the 98th percentile of Cardiovascular Disease profiles with reported payments. Percentile describes the distribution, not the conduct.

By program year

9 rows
Year Kind Relative to this record's peak year Amount Records
2025 General $103,958 148
2025 Research $7,463 11
2024 General $45,620 80
2024 Research $850 1
2023 General $10,738 50
2022 General $2,891 9
2021 General $20,000 4
2020 General $70,503 39
2019 General $64,047 71

Beside peers

Year by year, beside peers General payments · among profiles paid that year
  • Jaffar Khan
  • Cardiovascular Disease median
  • Middle half of Cardiovascular Disease
  • National median

In program year 2025, general payments to Jaffar Khan were reported at $103,958. Among 16,617 Cardiovascular Disease profiles paid that year, the median was $432 and the middle half received between $132 and $1,252.

Show as a table
Year Jaffar Khan Cardiovascular Disease median Middle half National median
2019 $64,047 $450 $127–$1,392 $163
2020 $70,503 $242 $77–$751 $114
2021 $20,000 $335 $101–$1,037 $132
2022 $2,891 $395 $121–$1,211 $149
2023 $10,738 $443 $136–$1,283 $160
2024 $45,620 $450 $136–$1,323 $164
2025 $103,958 $432 $132–$1,252 $169

Breakdown

Who paid General payments · program years 2019–2025
  1. Edwards Lifesciences Corporation $163,434 172 payments
  2. Medtronic, Inc. $78,094 133 payments
  3. Medtronic Vascular, Inc. $71,460 62 payments
  4. Abbott Laboratories $4,368 24 payments
  5. Shockwave Medical, Inc $186 1 payment
  6. Janssen Pharmaceuticals, Inc $54 2 payments
  7. Cardiovascular Systems Inc. $50 3 payments
  8. Boston Scientific Corporation $49 1 payment
  9. Cardiva Medical, Inc. $29 1 payment
  10. ZOLL Services LLC (A/K/A ZOLL LifeCor Corp) $21 1 payment
  11. Other $13 1 payment

Every payment, record by record

What the payments were for General payments · program years 2019–2025
  1. Consulting Fee $129,213 34 payments
  2. Compensation for services other than consulting, including serving as faculty or as a speaker at a venue other than a continuing education program $125,239 73 payments
  3. Travel and Lodging $40,052 104 payments
  4. Honoraria $14,063 4 payments
  5. Food and Beverage $9,191 186 payments
Products named General payments · program years 2019–2025
  1. EDWARDS SAPIEN 3 TRANSCATHETER HEART VALVE (THV) $95,755 57 payments
  2. COREVALVE EVOLUT R $77,870 127 payments
  3. CoreValve Evolut $71,401 61 payments
  4. Edwards SAPIEN 3 Transcatheter Heart Valve $55,560 37 payments
  5. SAPIEN 3 Ultra RESILIA $2,853 52 payments
  6. TRICLIP $2,807 6 payments
  7. NAVITOR Vascular $1,053 6 payments
  8. Edwards SAPIEN 3 Ultra Transcatheter Heart Valve $375 3 payments
  9. NAVITOR Structural Heart $248 6 payments
  10. PASCAL $234 8 payments
  11. Other $720 20 payments

A payment can name more than one product, so these amounts overlap and do not add up to the general-payment figure.

Research payments came from Research payments · program years 2019–2025
  1. Medtronic, Inc. $8,313 12 payments

Billing to Medicare

Part B · data year 2024 · 10 billing codes

Paid by Medicare

$4,683

Medicare's payments for the services billed

Medicare patients

42

Average age 81

Services billed

51

15 women, 27 men among their patients

Share of this provider's Medicare patients with each condition
Condition among their Medicare patients Relative to the most common Share of patients
High blood pressure 75%
Ischemic heart disease 75%
Heart failure 67%
Atrial fibrillation 67%
Arthritis 64%
Diabetes 50%
Chronic kidney disease 50%
COPD 38%

Medicare Part B only: services billed to Medicare. Rows covering fewer than 11 beneficiaries are not published. Only drugs given in the clinic are itemised here; the rest of what this provider billed is in the total above.

Records

413 reported

Every payment, record by record

Date, company, amount, what it was for and the product named — filter by year, kind and company, or download as CSV.

Other Cardiovascular Disease in District of Columbia

Related records

What this means

U.S. law requires drug and medical device manufacturers to report payments and transfers of value they make to physicians and teaching hospitals. The Centers for Medicare & Medicaid Services publishes that record each year. This page shows what was reported about this person, and nothing else.

An ownership interest is different from the other two. It is not a payment: it is a stake — shares, options, a partnership holding — that a physician or an immediate family member held in a manufacturer during that year. The figure shown is what the stake was reported to be worth.

Research payments frequently pass through a clinician to the institution running a trial, and rarely represent personal income. They should be read differently from general payments.

Provenance

Source: CMS Open Payments · through program year 2025

Data current to program year 2025, from CMS's 2026 publication.

We reproduce what manufacturers reported. We do not verify, edit or correct the underlying records.

A payment record is not evidence of wrongdoing. Financial relationships between industry and medicine are legal, common and often necessary for research. Who Paid My Doc reports what was disclosed; it does not judge it.

Who Paid My Doc is independent and is not affiliated with, endorsed by or sponsored by CMS or any U.S. government agency. It is not a consumer reporting agency and this is not a consumer report; do not use it for decisions covered by the Fair Credit Reporting Act.

How to dispute or correct a record